Evaluation of the Interleukin-1 Receptor Antagonist and Immunoregulatory Interleukin-10 in the Middle Ear in Chronic Otitis Media With Effusion in Children With and Without Atopy.
- Author:
Beata ZIELNIK-JURKIEWICZ
1
;
Wanda STANKIEWICZ-SZYMCZAK
Author Information
- Publication Type:Original Article
- Keywords: Interleukin-10; Interleukin-1 Receptor Antagonist; Otitis Media; Cytokines
- MeSH: Child*; Cytokines; Disease Progression; Ear, Middle*; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1*; Interleukin-10*; Otitis Media with Effusion*; Otitis Media*; Otitis*
- From:Clinical and Experimental Otorhinolaryngology 2016;9(2):104-108
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVES: The role of pro-inflammatory cytokines in the course of chronic otitis media with effusion (COME) has been documented. However, there are fewer studies on the action of anti-inflammatory cytokines in the middle ear. We sought determine whether there is an association between COME and anti-inflammatory cytokines and whether there are any differences in the cytokine profile in COME children with and without atopy. METHODS: Eighty-four children were divided into 3 groups: 32 nonatopic children with COME (group NA), 31 atopic children with COME (group A), and 21 children without COME and without atopy (control group C). Specimens from the middle ear were collected and evaluated by enzyme-linked immunosorbent assay for the cytokines interleukin-1 receptor antagonist (IL-1Ra) and immunoregulatory IL-10. RESULTS: Significantly higher IL-10 concentrations were found in both nonatopic and atopic children with COME compared to controls. No significant differences in IL-1Ra levels were found between atopic and nonatopic children with COME and the control group. CONCLUSION: We found no differences in the levels of IL-1Ra in atopic and nonatopic children with COME compared to controls. However, we found elevated IL-10 levels in the middle ear effusions from children with COME, with or without atopy. These elevated immunoregulatory cytokine levels suggest a role for new immunomodulatory treatments to prevent disease progression in COME, regardless of atopy.
